21583-31-3

Basic information

• Product Name: Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxy-m-methoxyphenyl)-
• Synonyms: 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-2-propen-1-one;2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-;Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxy-m-methoxyphenyl)-
• CAS NO: 21583-31-3
• Molecular Formula: C₁₆H₁₄O₅
• Molecular Weight: 286.27936
• Mol File: 21583-31-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxy-m-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxy-m-methoxyphenyl)-(21583-31-3)
• EPA Substance Registry System: Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxy-m-methoxyphenyl)-(21583-31-3)

Safety Data

• Hazardous Substances Data: 21583-31-3(Hazardous Substances Data)

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 121-33-5 vanillin 

Downstream Products

• 1027339-73-6 C₁₆H₁₆N₂O₄ 
• 13192-07-9 Liquiritigenin-5'-O-methyl ether 
• 1428324-85-9 1-(3-(2,4-dihydroxyphenyl)-5-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethan-1-one 

Relevant articles and documents

Glycolytic inhibition and antidiabetic activity on synthesized flavanone scaffolds with computer aided drug designing tools

Background: Diabetes mellitus is a challengeable metabolic disorder that leads to a group of complications when the HbA1c level is not maintained. Most of the existing drugs avail-able in the market in long-term use may lead to serious adverse effects. He

Pyrazoline-based mycobactin analogues as MAO-inhibitors

3,5-Diaryl carbothioamide pyrazolines designed as mycobactin analogs (mycobacterial siderophore) were reported to be potent antitubercular agents under iron limiting condition in our earlier study. Clinical complications of newly introduced antibiotic Linezolid, due its MAO inhibitory activity, prompted us to evaluate our compounds for their MAO-inhibitory activity against rat liver MAO-A and MAO-B as pyrazolines were reported to be antidepressants and MAO inhibitors. The present study carried out with this pilot library of 32 compounds will provide us with necessary information for designing antitubercular molecules with reduced MAO-inhibitory activity and also help us in identifying a selective MAO-B inhibitor which has potential clinical utility in neurodegenerative disorders. Thirty-two compounds analyzed has shown spectrum of activity from selective to nonselective against two isoforms of rat liver MAO-A and MAO-B and also as competitive, reversible to non-competitive, irreversible. It is also interesting to note that anti-tubercular compound 11, 14 and 16 were also found to be selective inhibitors of rat liver MAO-B. Docking studies with human MAO shows that compound 11 interacts with the catalytic site of both the isoforms, suggesting compound 11 as nonselective inhibitor of human MAO isoforms.